

Pfizer: Mid-November earliest it can seek virus vaccine OK

16 October 2020



In this Feb. 26, 2019 file photo, Albert Bourla, chief executive officer of Pfizer, prepares to testify before the Senate Finance Committee hearing on drug prices, on Capitol Hill in Washington. Pfizer Inc.'s CEO says it can't seek emergency authorization of its COVID-19 vaccine before the third week of November—and that's if everything goes well. The announcement on Friday, Oct. 16, 2020, by Bourla reflects estimates from leading scientists that its unlikely data would start to emerge until November or December showing any of the leading vaccine candidates work. (AP Photo/Pablo Martinez Monsivais, File)

Pfizer Inc. cannot request emergency authorization of its COVID-19 vaccine before the third week of November—and that's if everything goes well, the company's CEO announced Friday.

Despite President Donald Trump's repeated promises of a vaccine before Election Day, scientists have been cautioning that it's unlikely data showing a leading shot actually works would come until November or December.

Another leading U.S. contender, Moderna Inc., previously announced the earliest it could seek authorization of its own vaccine would be Nov. 25.

Pfizer CEO Albert Bourla has long said it's possible testing might reveal by the end of October if his company's vaccine actually protects against the coronavirus. But in Friday's announcement, he made clear that effectiveness is only part of the equation.

The vaccine also must be proven safe. And to qualify for an "emergency use authorization," any COVID-19 vaccine must track at least half the participants in large-scale studies for two months after their second dose, the time period in which side effects are likely to appear.

Bourla estimated Pfizer's 44,000-person study will reach that milestone in the third week of November.

"We are operating at the speed of science," he wrote in a letter posted to the company's website.

The vaccine made by Pfizer and its German partner BioNTech are among several leading candidates in final testing.

Even if a vaccine emerges by year's end, only limited doses will be available right away. The U.S. government is deciding who would be first in line, almost certainly health care workers, and estimates there may be enough for widespread vaccinations in the spring.

© 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.



APA citation: Pfizer: Mid-November earliest it can seek virus vaccine OK (2020, October 16) retrieved 3 May 2021 from https://medicalxpress.com/news/2020-10-pfizer-authorization-covid-vaccine-november.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.